Document:

ex32-2.htm

    
         

    

    Adamis Pharmaceuticals Corporation 10-K

    
         
    

    
        Exhibit 10.22
    

    
         

CERTAIN MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT
BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH OMITTED
INFORMATION IS INDICATED BY BRACKETS (“[...***...]” IN THIS EXHIBIT.

	November 21, 2014	
    Dennis J. Carlo, Ph.D.

    President &
    CEO

 

	Personal and Confidential	[***]  

David Dwight C. Benedicto

[***]

Dear Mr. Benedicto:

We are pleased to offer you the full-time position
with Adamis Pharmaceuticals Corporation (“Company”) of Accounting Manager based in San Diego, CA. We anticipate that, following
your acceptance of this offer, your full-time employment will commence no later than [***], or a date to be mutually agreed by the Company
and you.

You will report to the Chief Financial Officer
will be paid at the rate of $9,166.67 per month during your employment, which reflects an annualized amount of $110,000. Your position
is classified as exempt, which means, in part, that your work for the Company is not subject to the laws related to tracking of daily
hours of work, minimum wage, overtime or meal and rest periods (and therefore, you will not be eligible for overtime). You will be paid
in accordance with the Company’s normal payroll practices; currently, the Company provides for payment of salaries and wages on
a semi-monthly basis. Compensation is subject to adjustment (upwards or downwards) as the discretion of the Company or the compensation
committee of the Board. All compensation and other payments described hereunder are subject to and will be reduced by normal payroll withholdings
and the Company’s standard payroll practices.

As a full-time employee, you will be eligible
for participation in the Company’s annual bonus program that currently provides for a bonus of up to [***] of your base salary.
As a full time employee, you will also be entitled to receive other benefits as are currently provided to employees generally by Company
policies from time to time, subject to applicable eligibility requirements. These benefits currently include Company paid [***] insurance.
[***] insurance are available at the option and expense of the employee. All plans are available to you on the 1st day of the
month following your start date.

You will be entitled to [***] vacation days
([***] hours) each year which will be prorated for a partial year. Employees can accrue to a maximum one and a half times their annual
eligibility. You will also receive [***] holidays. Vacation, paid sick leave, and holidays are detailed in the Company’s employee
manual. You agree to comply with Company policies, including those set forth in the Company’s employee manual.

As a full-time employee, your compensation
will generally be reviewed annually in a manner similar to other employees generally, and you will be eligible for additional performance
based compensation in a manner similar to other employees generally, in the sole discretion of the Company and the Board.

In addition, we will recommend that the Board
or tire compensation committee of the Board approve the grant to you, under the Company’s 2009 Equity Incentive Plan, of an incentive
stock option to purchase [***] shares of common stock, with terms and conditions (including vesting) to be described in the option grant
and related option agreement. The exercise price will be equal to the fair market value of the common stock on the date of grant, determined
as provided in the plan.

    	 	11682 El Camino Real	Suite 300	San Diego, CA	92130	 

     

    

 

You should be aware that your employment with
the Company is for no specific period and constitutes at will employment. As a result, you are free to resign at any time, for any reason
or for no reason. Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause,
and without notice. The at-will status of your employment cannot be changed except in writing executed by a duly authorized officer of
the Company. Additionally, your duties, title, compensation, benefits, and reporting structure may be changed or modified at any time
at the discretion of the Company, with or without notice.

Please be advised that our offer of employment
is conditioned upon you signing the Company’s standard employee proprietary information and invention assignment agreement or similar
agreement, in such form and substance as the Company may require, and such other agreements and instruments that the Company customarily
requires new employees to execute. For purposes of federal immigration law, you will be required to provide to the Company documentary
evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three
(3) business days of your date of hire, or our employment relationship with you may be terminated. The Company also reserves the right
to conduct background investigations and/or reference checks on all of its potential employees, and therefore your employment may be contingent
upon a clearance of such a background investigation and/or reference check, if any.

You agree to devote your full time, attention
and skills solely to working for the Company and performing the duties assigned or delegated to you. You agree that, during the term of
your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly
related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage
in any other activities that conflict with your obligations to the Company.

You agree that you will not, during your employment
with the Company, improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity
or violate any confidentiality, proprietary information or similar agreement between you mid any former employer, and that you will not
bring onto the premises of the Company any unpublished document or proprietary information belonging to any such employer, person, or
entity unless consented to in writing by such employer, person, or entity. You represent to the Company that you are not subject to any
obligation, contractual or otherwise, that prevents or restricts you from becoming employed by the Company. You also represent that you
understand that the Company is in the early stages of development and that there are high risks associated with employment at such a company.

As a Company employee, you will be expected
to abide by company rules and regulations. You will be specifically required to sign an acknowledgment that you have read and understand
the company rules of conduct, which are included in our handbook.

    	 	11682 El Camino Real	Suite 300	San Diego, CA	92130	 

     

    

 

In the event of any dispute or claim relating
to or arising out of our employment relationship, you and the Company agree to initially attempt to resolve the issue informally or with
the assistance of a neutral, outside mediator. If a dispute cannot be resolved by these means, the sole and exclusive means of final dispute
resolution is through binding arbitration, as described in the Company’s arbitration policy and/or the proprietary information agreement.
Note that this paragraph is only a short summary of the Adamis employment dispute resolution process.

In the event of termination of your employment
with the Company, or at any other time at the Company’s request, you agree to deliver promptly to the Company all property of the
Company that is in your possession or control, including but not limited to computers, data, software, cell phones, drawings, manuals,
correspondence, notes, notebooks, sketches, formulae, records, emails, service parts, memoranda, access cards or keys to the Company’s
facilities, equipment or vehicles, and all other materials relating to the Company’s business or which contain proprietary information.
You further agree not to make or retain copies of any of the foregoing and will so represent to the Company upon termination of employment.

To indicate your acceptance of the Company’s
offer, please sign and date this letter in the space provided below and return it to me in an email as well as in the self-addressed stamped
envelope. A duplicate original is enclosed for your records.

This letter, along with the agreement relating
to proprietary rights between you and the Company, set forth the terms of your employment with the Company and supersede any prior representations
or agreements, whether written or oral. This letter may not be modified or amended except by a written agreement, signed by an officer
of the Company and by you.

Please acknowledge your acceptance in the foregoing
offer by signing in the space below. This offer will be considered null and void if a signed copy is not returned within [***] business
days of the date of this letter.

We look forward to you joining the team at
Adamis Pharmaceuticals and contributing to our success.

Sincerely,

 

/s/ Dennis J. Carlo      

Dennis J. Carlo, Ph.D.

President & CEO

ACCEPTED AND AGREE TO this 21st day of November,
2014.

 

 

/s/ David Dwight C. Benedicto

David Dwight C. Benedicto

		Enclosures:	Duplicate Letter

Confidentiality Agreement

      

    	 	11682 El Camino Real	Suite 300	San Diego, CA	92130Adamis Pharmaceuticals Corporation 10-K

    
         
    

    Exhibit
    10.45

 

 

Confidential

 

CERTAIN
MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY
AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH OMITTED INFORMATION IS INDICATED BY BRACKETS (“[...***...]”
IN THIS EXHIBIT.

 

FIRST
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

This
Amendment No. 1 (“Amendment No. 1”) is dated this 9th day of November by and between Matrix Biomed, Inc., a Delaware
corporation (“Licensor”), on the one hand, and Adamis Pharmaceuticals, a Delaware corporation (the “Licensee”),
on the other hand, to amend the terms of that certain License Agreement entered into by and between the parties dated June 12, 2020 (the
“LICENSE AGREEMENT”). Licensor and Licensee shall be referred to herein as a “Party” and collectively as the
“Parties”. In the event the terms of the LICENSE AGREEMENT and this Amendment No. 1 conflict, the terms of this amendment
No. 1 control. Any defined terms herein that are not defined herein have the meaning set forth in the LICENSE AGREEMENT.

RECITALS

WHEREAS,
in the LICENSE AGREEMENT Licensor granted Licensee a license to the Licensed Patents and Related Know How (as defined below) solely for
the purpose of developing, producing and selling Licensed Products within the Licensed Field of Use.

WHEREAS,
the Parties now wish to amend the scope of the patent grant set forth in said License Agreement at Section 1.8 therein; and

WHEREAS,
the parties now wish to amend the License Agreement on the terms set forth herein;

NOW,
THEREFORE, in consideration of the mutual covenants and License Agreements set forth below, the parties agree as follows:

AMENDMENT

	1.	Terms.
                                            Capitalized terms in this Amendment shall have the same meaning as those in the License Agreement,
                                            unless specifically defined in this Amendment. All section and paragraph references refer
                                            to sections or paragraphs as applicable, in the License Agreement. References to the term
                                            “License Agreement” in the License Agreement shall be deemed to include the Amendment.
	 	 
	2.	This
                                            First Amendment shall be effective as of the date the last party hereto has executed this
                                            First Amendment (the “First Amendment Date”).

 

 

    	LICENSEE/LICENSOR 1st Amendment
	 	 

    Confidential

    

 

 

	3.	For
                                            the convenience of the parties hereto, this First Amendment may be executed in two counterparts,
                                            each of which shall me deemed to be an original, but both of which together shall constitute
                                            one and the same instrument, without necessity of production of the others. Signatures may
                                            be exchanged by electronic transmission and each of the parties to this First Amendment agrees
                                            that it will be bound by its own facsimile signature and that it accepts the facsimile signature
                                            of the other party.
	 	 
	4. 	Amendment
                                            to Section 3 of the LICENSE AGREEMENT to hereby include the following paragraph:

		3.1.1	Licensor
                                            also grants a license to license in US Patent Number [***] issued [***] based upon U.S. Patent
                                            Application Serial Number [***] entitled [***] exclusively for the treatment of SARS-COV-2
                                            (COVID-19) in the Licensed Territory.

	5.	Amendment to Section 7.2.2 of the LICENSE AGREEMENT to:

		7.2.2	Licensor
                                            has sole control over whether to bring suit upon learning of infringement and shall control
                                            any litigation, claim, action or proceeding it initiates, including the selection of counsel.
                                            Licensee may retain additional counsel of its own selection and at its own expense to observe
                                            the litigation and to advise or assist Licensor. Licensor and its counsel will cooperate
                                            with and seek the input of Licensee’s counsel in such matters.

	6.	Delete Section 7.2.3.

 

    	LICENSEE/LICENSOR 1st Amendment
	 	 

    Confidential

    

 

 

IN
WITNESS WHEREOF, the parties have executed this Agreement effective as of the day and year first above the written.

 

	 	“LICENSOR”	 
	 	 	 
	 	Matrix
Biomed, Inc,	 
	 	a
Delaware Corporation	 
	 	 	 
	 	 	 
	 	By:	/s/ Allyn Burroughs	 
	 	 	Allyn Burroughs, Chairman	 
	 	 	 
	 	 	 
	 	“LICENSEE”	 
	 	 	 
	 	Adamis Pharmaceuticals, Inc.	 
	 	a Delaware Corporation	 
	 	 	 
	 	 	 
	 	By:	/s/ Dennis J. Carlo	 
	 	 	Dennis J. Carlo, CEO and President	 

 

 

 

    	LICENSEE/LICENSOR 1st Amendment

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]